K
K. Miki
Researcher at University of Tokyo
Publications - 3
Citations - 1201
K. Miki is an academic researcher from University of Tokyo. The author has contributed to research in topics: Population. The author has an hindex of 3, co-authored 3 publications receiving 1116 citations.
Papers
More filters
Journal ArticleDOI
Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)
Mário Dinis-Ribeiro,Miguel Areia,A C de Vries,Ricardo Marcos-Pinto,Matilde Monteiro-Soares,Anthony O'Connor,Carina Pereira,Pedro Pimentel-Nunes,Ricardo Correia,Arzu Ensari,Jean-Marc Dumonceau,José Carlos Machado,Guilherme Macedo,Peter Malfertheiner,Tamara Matysiak-Budnik,Francis Megraud,K. Miki,Colm Antoine O’Morain,Richard M. Peek,Thierry Ponchon,Ari Ristimäki,Ari Ristimäki,B. Rembacken,Fátima Carneiro,Ernst J. Kuipers +24 more
TL;DR: A multidisciplinary group of 63 experts from 24 countries developed evidence-based guidelines on the management of patients with precancerous conditions and lesions of the stomach by means of repeat online voting and a meeting in June 2011 in Porto, Portugal.
Journal ArticleDOI
Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)
Mário Dinis-Ribeiro,Miguel Areia,A C de Vries,Ricardo Marcos-Pinto,Matilde Monteiro-Soares,Anthony O'Connor,Carina Pereira,Pedro Pimentel-Nunes,Ricardo Correia,Arzu Ensari,Jean-Marc Dumonceau,José Carlos Machado,Guilherme Macedo,Peter Malfertheiner,Tamara Matysiak-Budnik,Francis Megraud,K. Miki,Colm Antoine O’Morain,Richard M. Peek,Thierry Ponchon,Ari Ristimäki,Ari Ristimäki,B. Rembacken,Fátima Carneiro,Ernst J. Kuipers +24 more
TL;DR: The recommendations emphasize the increased cancer risk in patients with gastric atrophy and metaplasia and the need for adequate staging in the case of high-grade dysplasia, and they focus on treatment and surveillance indications and methods.
Journal ArticleDOI
Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening.
TL;DR: Pepsinogen test definition should include pepsinogen I/II ratio as consistency was obtained, both in population based studies and in selected groups for those studies that used pepsInogen I serum levels together with peps inogen I-II ratio for screening for gastric cancer in high-incidence regions other than Japan.